Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

4.5%

1 terminated/withdrawn out of 22 trials

Success Rate

92.9%

+6.4% vs industry average

Late-Stage Pipeline

64%

14 trials in Phase 3/4

Results Transparency

15%

2 of 13 completed trials have results

Key Signals

3 recruiting2 with results

Enrollment Performance

Analytics

Phase 4

13(86.7%)

N/A

1(6.7%)

Phase 3

1(6.7%)

15Total

Phase 4(13)

N/A(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (22)

Showing 20 of 22 trials

NCT05164263Phase 4Recruiting

Real World Safety & Efficacy Experience of Empagliflozin With or Without Metformin in T2DM Patients - EASE Study

Role: lead

NCT07174297Phase 3Not Yet Recruiting

Acotiamide vs Itopride in Postprandial Distress Syndrome

Role: lead

NCT05977647Phase 4Completed

Medical Stone Expulsive Therapy for Acutely Obstructed Ureteric Calculi

Role: lead

NCT07031141Not Yet Recruiting

Diabetes Foot Africa Region Registry

Role: lead

NCT05644717Phase 4Recruiting

Effect of Erugliflozin On Liver Fat, Liver Fibrosis and Glycemic Control in Type II DM Patients With NASH/NAFLD

Role: lead

NCT05556291Completed

Combination of Ertugliflozin And Sitagliptin Efficacy, Safety & Tolerability (CEASE Diabetes) Study

Role: lead

NCT06706609Not Yet Recruiting

Classification of Adult-onset Diabetes in Five Subgroups in Pakistani Population

Role: lead

NCT05973188Phase 4Unknown

Safety and Efficacy of Rivaroxaban and Apixaban in Comparison to Warfarin in Left Ventricular Clot- Clinical Trial

Role: collaborator

NCT05156736Recruiting

Pakistan Study of Premature Coronary Atherosclerosis in Young Adults

Role: collaborator

NCT05161741Phase 4Completed

Research on Human Insulin rDNA Safety and Efficacy in Patients With Type 2 Diabetes Mellitus

Role: lead

NCT05167513Phase 4Completed

Monitoring Parameters Beyond Glycemic Control: Impact of Sitagliptin on Quality of Life in Type 2 Diabetes Patients

Role: lead

NCT05359432Phase 4Completed

Comparison of Empaglifozin and Vildagliptin in Type 2 Diabetes Mellitus

Role: lead

NCT04976283Phase 4Unknown

Effect of Oral Anti-diabetic Medication on Liver Fat in Subjects With Type II Diabetes and Non-alcoholic Fatty Liver

Role: lead

NCT04664894Completed

Direct Acting Anti-Viral's In Chronic HCV Patients

Role: lead

NCT04665284Phase 4Completed

Safety And Efficacy Of Empagliflozin In Pakistani Muslim Population With Type Ii Diabetes Mellitus

Role: lead

NCT04301219Completed

Knowledge and Practices of ADR Reporting in LMICs

Role: lead

NCT02600780Phase 4Completed

Zurig (Febuxostat) 40mg Efficacy and Safety Trial

Role: lead

NCT03710057Completed

Effect of Ivabradine in Lowering Heart Rate and Quality of Life in Chronic Heart Failure Patients

Role: lead

NCT02601976Phase 4Completed

Evaluation of Unipeg® for Response and Ongoing Safety in Pakistani Population

Role: lead

NCT01770483Phase 4Completed

The Role Of Nitazoxanide, Interferon Alfa And Ribavirin In Treatment Of Hepatitis C Infected Type 2 Diabetic Patients

Role: collaborator